Table 4. Clinical characteristics of hemodialysis patients who were CAP-identified HS with or without US-identified HS.
| Variables | CAP ≥ 238 dB/m combined with US-identified HS (N = 62) | CAP ≥ 238 dB/m without US-identified HS (N = 101) | P value |
|---|---|---|---|
| Age(yr) | 63.9±10.1 | 64.3±10.5 | 0.825 |
| Male | 27 (43.6%) | 45 (44.6%) | 0.900 |
| BMI (kg/m2) | 0.029 | ||
| <24 | 29 (47.5%) | 64 (63.4%) | |
| 24–30 | 26 (42.6%) | 35(34.7%) | |
| >30 | 6 (9.9%) | 2 (1.9%) | |
| DM (%) | 27 (43.6%) | 36 (35.6%) | 0.314 |
| AST (IU/L) | 19.6±6.6 | 19.0±7.0 | 0.616 |
| ALT (IU/L) | 17.4±11.4 | 15.6±9.4 | 0.269 |
| Bilirubin (mg/dL) | 0.3±0.1 | 0.3±0.2 | 0.299 |
| Albumin (g/dL) | 4.0±0.3 | 3.9±0.3 | 0.255 |
| Fasting sugar (mg/dL) | 178.8±111.9 | 150.7±59.3 | 0.039 |
| HDL, male< 40, female < 50(mg/dL) | 48 (78.7%) | 62 (63.3%) | 0.041 |
| LDL (mg/dL) | 84.7±27.5 | 91.1±33.0 | 0.209 |
| Total cholesterol (mg/dL) | 163.3±35.3 | 169.0±38.4 | 0.351 |
| VLDL(mg/dL) | 41.5±18.7 | 33.1±17.9 | 0.006 |
| Triglyceride >150 (mg/dL) | 42 (67.7%) | 51 (51.0%) | 0.036 |
| Platelet<150 (1000/μL) | 15 (24.2%) | 24 (24.0%) | 0.978 |
| LSM (kPa) | 6.7 (5.3–8.6) | 6.3 (4.9–8.2) | 0.931 |
| CAP (dB/m) | 281 (250–310) | 268 (250–286) | 0.061 |
BMI, body mass index; DM, diabetes mellitus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, High-density lipoprotein; CAP, Controlled Attenuation Parameter; LSM, liver stiffness measurement; LDL, low-density lipoprotein; VLDL, Very-low-density lipoprotein